EUVIMEDEUVIMED entdecken
Crossref

Incorrect perceptions of first-line treatment of severe allergic reactions with over-the-counter products and how the epinephrine drug delivery system impacts behavior

Raffi Tachdjian, Nicole Chase, Autumn Burnette, David Kaufman, Sarina Tanimoto, Ayman Kafal

Allergy and Asthma Proceedings · 2026

DOI: 10.2500/aap.2026.47.250082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy and Asthma Proceedings, 2026. Verfasst von Raffi Tachdjian und 5 weiteren Autor:innen. Beteiligte Einrichtung: From the David Geffen School of Medicine, University of California, Los Angeles, California. Hauptthemen laut MEDLINE: Epinephrine, Nonprescription Drugs, Anaphylaxis, Drug Delivery Systems. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epinephrine is the first-line treatment for anaphylaxis, a potentially life-threatening allergic reaction. Despite this, real-world epinephrine use remains suboptimal.

Objective

In this survey study of patients and caregivers of patients with anaphylaxis, the objective was to characterize real-world use of over-the-counter (OTC) medications alone or before epinephrine and to evaluate factors inherent to epinephrine delivery devices in contributing to delayed epinephrine use.

Methods

Participants included U.S. patients (n = 100) and caregivers of patients with immunoglobulin E (IgE) mediated allergy (n = 100) who used an epinephrine autoinjector (EAI) in the past 12 months. A double-blind online survey evaluated allergy history, management of severe allergic reactions, and reasons for delaying epinephrine use.

Results

Most respondents reported using OTC medications alone (88%) or before using an EAI (89%) to manage allergic reactions. During their most recent reactions, 42% of the respondents delayed or hesitated to use an EAI, with an average of 8.8 minutes before administration. The most impactful factor that contributes to delayed EAI use was concern about the device needle. Respondents who reported using OTC medications to manage most allergic reactions estimated that they would use needle-free epinephrine over OTC medications approximately three-fourths of the time.

Conclusion

Despite potential risks of delaying using epinephrine, OTC medications are commonly used alone or before epinephrine use. Given the concerns about device needles identified in this survey, needle-free epinephrine offers an alternative to EAIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpinephrineNonprescription DrugsAnaphylaxisDrug Delivery SystemsHypersensitivityHumansFemaleAdultMaleMiddle AgedSurveys and QuestionnairesAgedYoung AdultImmunoglobulin EPerceptionAdolescent

Substanzen

EpinephrineNonprescription DrugsImmunoglobulin E

Autor:innen und Institutionen

  • From the David Geffen School of Medicine, University of California, Los Angeles, California.
  • University of Minnesota, Minneapolis, Minnesota.
  • Howard University Hospital, Washington, D.C.
  • LSU Health Shreveport, Shreveport, Louisiana; and.
  • ARS Pharmaceuticals Operations, San Diego, California.

Zitieren

APA

Tachdjian, R., Chase, N., Burnette, A., Kaufman, D., Tanimoto, S., & Kafal, A. (2026). Incorrect perceptions of first-line treatment of severe allergic reactions with over-the-counter products and how the epinephrine drug delivery system impacts behavior. Allergy and Asthma Proceedings. https://doi.org/10.2500/aap.2026.47.250082

Vancouver

Tachdjian R, Chase N, Burnette A, Kaufman D, Tanimoto S, Kafal A. Incorrect perceptions of first-line treatment of severe allergic reactions with over-the-counter products and how the epinephrine drug delivery system impacts behavior. Allergy and Asthma Proceedings. 2026. doi:10.2500/aap.2026.47.250082

BibTeX
@article{Tachdjian2026,
  author = {Tachdjian, Raffi and Chase, Nicole and Burnette, Autumn and Kaufman, David and Tanimoto, Sarina and Kafal, Ayman},
  title = {Incorrect perceptions of first-line treatment of severe allergic reactions with over-the-counter products and how the epinephrine drug delivery system impacts behavior},
  journal = {Allergy and Asthma Proceedings},
  year = {2026},
  doi = {10.2500/aap.2026.47.250082}
}
Kostenlos starten →